1 | Date | Speaker | Title | Affiliation | |
|---|---|---|---|---|---|
2 | Upcoming: | ||||
3 | 4/24/2026 | Tom Williams, MD, PhD | The Profound Benefits of Sickle Cell Trait to Children Born in Africa | Imperial College, London | |
4 | 5/22/2026 | TBA | TBA | ||
5 | 6/26/2026 | TBA | TBA | ||
6 | |||||
7 | Past talks: | ||||
8 | 3/27/2026 | Shannon McKinney-Freeman, PhD | Senolytics Restore Function to the Bone Marrow During Sickle Cell Disease | ||
9 | 2/27/2026 | Allan Doctor, MD | RBC eNOS Regulates O2 Delivery Homeostasis: Disruption in Sickle Cell Disease | University of Maryland School of Medicine | |
10 | 1/23/2026 | Scott Peslak, MD, PhD | Novel regulators of fetal hemoglobin in the treatment of sickle cell disease | University of Pennsylvania Perelman School of Medicine | |
11 | 12/26/2025 | Canceled | Winter Holiday | ||
12 | 11/28/2025 | Canceled | Thanksgiving Break | ||
13 | 10/31/2025 | Russell Ware, MD, PhD | Halloween Hydroxyurea: Teaching an Old Ghoul New Tricks | Cincinnati Children's Hospital | |
14 | 9/26/2025 | Mariam Kayle, PhD | Leveraging Data to Advance Sickle Cell Outcomes in NC | Duke University School of Nursing | |
15 | 8/22/2025 | Elizabeth Klings, MD | Venous thromboembolism and Impact on clinical outcomes in SCD | Boston University Medical Center | |
16 | 7/25/2025 | Shannon McKinney-Freeman, PhD | Stem Cell Senescence in Sickle Cell Disease | St. Jude Children's Research Hospital | |
17 | 6/27/2025 | Swee Lay Thein, MD, DSc, FMedSci | Activating Pyruvate Kinase in Sickle Cell Disease | National Institutes of Health (NIH) | |
18 | May | -summer | break- | ||
19 | 4/25/2025 | Elizabeth Traxler, MD, PhD | Novel Genome Editing Approaches to Decode Fetal Hemoglobin Regulation | University of Pennsylvania | |
20 | 3/10/2025 | Martha Kenney, MD | Nociplastic Pain in Sickle Cell Disease: Is it the Missing Piece of the Puzzle? | Duke University School of Medicine | |
21 | 2/10/2025 | David A. Williams, MD | Recent Developments in Gene Therapy | Harvard Medical School | |
22 | 10/14/2024 | Sarah O'Brien, MD, MSc | Hormonal Contraceptive in Patients Living with Sickle Cell Disease: Benefits, Risks and All the Unknowns in Between | Nationwide Children's Hospital | |
23 | 11/11/2024 | Ann Kinga Malinowski, MD, MSc, FRCSC | Sickle Cell Disease in Pregnancy | Sinai Health System | |
24 | 7/8/2024 | Erica Sparkenbaugh, PhD | Tipping the Balance – Inducing Protective PAR1 Signaling in Sickle Cell Disease | University of North Carolina at Chapel Hill, Blood Research Center | |
25 | 6/10/2024 | Charles Quinn, MD, MS | Current Therapeutics for Pediatric SCD | Cincinnati Children's Hospital Medical Center | |
26 | 3/11/2024 | Eugenia Vicky | Asare, MBChB | The Power of Multidisciplinary Expertise: Lessons from the Korle-Bu Teaching Hospital, Accra, Ghana | Ghana Institute of Clinical Genetics, Korle-Bu Teaching Hospital |
27 | 2/12/2024 | Zena | Quezado, MD | Ketamine as an Adjuvant to Opioids in Sickle Cell Pain | National Institutes of Health |
28 | 1/8/2024 | Julie | Kanter, MD | Gene Therapies for Sickle Cell Disease | |
29 | 11/13/2023 | Rafaella | Colombatti, MD, PhD | SCD Data Collection in Europe: challenges and opportunities | |
30 | 10/9/2023 | Lachelle | Weeks, MD, PhD | Risk Stratification in Clonal Hematopoiesis – Implications for Curative Therapy in Sickle Cell Disease | |
31 | 9/11/2023 | Monica | Hulbert, MD | 5th Annual SiNERGe Symposium Keynote Speech | |
32 | 7/10/2023 | Satheesh | Chonat, MD | Complement in Sickle Cell Disease | |
33 | 6/12/2023 | Pat | Carroll, MD | [Buprenorphine] | |
34 | Sophie | Lanzkron, MD, MHS | |||
35 | 5/8/2023 | Luke | Smart, MD | TCD screening and stroke prevention in sub-Saharan Africa | |
36 | 3/13/2023 | Jane | Little, MD | Hypoxia at night: who has it? What does it mean? | |
37 | 2/13/2023 | Stella | Chou, MD | RH genotyping to improve red cell matching for individuals with SCD | |
38 | 1/9/2023 | Erica | Esrick, MD | Gene therapy for sickle cell disease | |
39 | 12/19/2022* | Umut | Gurkan, PhD | Microfluidic Imaging Systems for Single-Cell Level Mechanobiology and Biophysics Studies of Blood Cells | |
40 | 11/14/2022 | Veronica | Carullo, MD, FAAP | Beyond the crisis: What's new in pain management in sickle cell disease? | |
41 | & Kerry | Morrone, MD | |||
42 | 10/10/2022 | Brian | Laurence, DDS, PhD | Oral health and sickle cell disease: the role of access to care | |
43 | 9/12/2022 | Joshua | Field, MD, MS | The Role of Circulating Fibrocytes in Sickle Cell Lung Disease | |
44 | August | -summer | break- | ||
45 | July | -summer | break- | - | |
46 | 6/13/2022 | Ambroise | Wonkam, PhD | The Genomics Keys of Sickle-Cell Disease Therapeutics | |
47 | 5/9/2022 | Courtney | Fitzhugh, MD | Clonal Hematopoiesis Following Curative Therapies for Sickle Cell Disease | |
48 | 4/11/2022 | Mary | Eapen, MRCPI, MS, MBBS | Hematopoietic cell transplant for sickle cell disease: Built to last? | |
49 | 3/14/2022 | Andrew | Heitzer, PhD | Neuropsychological Functioning in Sickle Cell Disease: Risk and Protective Factors | |
50 | 2/14/2022 | Arthur | Burnett, MD | New Management Paradigm for Recurrent Ischemic Priapism | |
51 | 1/17/2022 | Eugene | Oteng-Ntim, MBBs MRCOG PGDip FRCOG | Sickle Cell disease in Pregnancy: When the miracle of childbirth becomes a matter of life and death | |
52 | 11/8/2021 | William | Zempsky, MD, MPH | Drowning in a sea of pain: Chronic pain in sickle cell disease | |
53 | 10/11/2021 | Karina | Yazdanbakhsh, PhD | Hemolysis and immune activation in sickle cell disease | |
54 | 9/13/2021 | Venée | Tubman, MD, MMSc | The Spleen in Sickle Cell Disease: Gone but Not Forgotten | |
55 | 7/12/2021 | Marcus | Carden, MD | Emergency department use of intravenous fluids and outcomes in pediatric and adult patients with sickle cell disease: from the bench and bedside | |
56 | 6/14/2021 | Wally | Smith, MD | Race, Science, and Medicine | |
57 | 5/10/2021 | Guillaume | Lettre, PhD | A Genetic Perspective on Clinical Heterogeneity in Sickle Cell Disease | |
58 | 4/12/21 | Swee Lay | Thein, M.B., B.S., F.R.C.P., F.R.C.Path., D.Sc., FMedSci | Utilizing AI and machine learning to derive A Phenotypic Risk Score for Prediction of Mortality in Sickle Cell Disease | |
59 | Xin | Tian, PhD | |||
60 | Vandana | Sachdev, MD | |||
61 | 3/8/2021 | Mark | Walters, MD | Curative Therapies for Sickle Cell Disease | |
62 | 2/8/2021 | Patrick | McGann, MD MS | Optimization of Hydroxyurea Use through Precision Medicine: Experience in Children and Next Steps for Adults | |
63 | 1/25/2021 | Claudia | Morris, MD | New Perspectives on Arginine Therapy in Sickle Cell Disease | |
64 | 11/9/2020 | Mitchell | Weiss, MD PhD | Genome Editing for Sickle Cell Disease | |
65 | 10/26/2020 | Kalpna | Gupta, PhD | Pain in Sickle Cell Disease: Working Towards the Challenge | |
66 | 10/12/2020 | Lydia | Pecker, MD | From Anecdote to Data: Fertility and Fertility Preservation in Girls and Women with SCD | |
67 | 9/28/2020 | Jeffrey | Lebensburger, MD | Pediatric Renal Manifestations of Sickle Cell Disease | |
68 | 9/14/2020 | Roberto | Machado, MD | Understanding Pulmonary Complications of Sickle Cell Disease: A Precision Medicine Approach | |
69 | 8/31/2020 | Melanie | Fields, MD | Using MRI to Understand the Impact of Sickle Cell Anemia on Brain Development | |
70 | 8/24/2020 | Thomas | Coates, MD | Iron Overload, the Short and the Long of it: Lessons from Rare Transfusion Dependent Anemias | |
71 | 8/17/2020 | Santosh | Saraf, MD | Sickle Cell Nephropathy | |
72 | & Vimal | Derebail, MD, MPH, FASN | |||
73 | 8/3/2020 | Caterina | Minniti, MD | Leg Ulcers in sickle Cell Disease: approaches to management | |
74 | 7/27/2020 | John | Tisdale, MD | Toward curative therapies for sickle cell disease, where do we stand? | |
75 | 7/20/2020 | Theodore | Wun, MD, FACP | Thick and Thin: Clotting and Bleeding in Patients with Sickle Cell Disease | |
76 | 7/13/2020 | Kenneth | Ataga, MD | The Evolving Landscape of Drug Therapies in Sickle Cell Disease | |
77 | 7/6/2020 | JJ | Strouse, MD, PhD | Functional Assessment for Adults with Suckle Cell Disease | |
78 | 6/29/2020 | Jane | Hankins, MD, MS | What transition to adult care can teach us about cohort studies in SCD | |
79 | 6/22/2020 | John C. | Wood, MD, PhD | Pathophysiology of white matter damage in Sickle Cell Disease: Challenges and Controversies | |
80 | 6/15/2020 | Marsha | Treadwell, PhD | Patient Reported Outcome Measures in Sickle Cell Disease | |
81 | 6/8/2020 | Dan | Bauer, MD, PhD | Gene Editing for Sickle Cell Disease | |
82 | 6/1/2020 | Marcus | Bankes, BSc, FRCS | Avascular Necrosis in Sickle Cell Disease | |
83 | 5/18/2020 | Vivien | Sheehan, MD, PhD | Red Cell Rheology: Biomarkers to evaluate sickle cell disease therapies | |
84 | 5/11/2020 | Allison | King, MD, MPH, PhD | Cognitive Health and Sickle Cell Disease: Screen to Intervene | |
85 | 5/4/2020 | Jo | Howard, MB Bchir, MRCP, FRCPath | An update on transfusion in sickle cell disease: ASHguidelines and (a little) on COVID-19 | |
86 | |||||
87 | |||||
88 | |||||
89 | |||||
90 | |||||
91 | |||||
92 | |||||
93 | |||||
94 | |||||
95 | |||||
96 | |||||
97 | |||||
98 | |||||
99 | |||||
100 | |||||
101 | |||||
102 | |||||
103 | x | ||||